Fiche publication


Date publication

juillet 2020

Journal

Journal of the European Academy of Dermatology and Venereology : JEADV

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LIPSKER Dan


Tous les auteurs :
Reymann V, Bessis D, Bergeret B, Lipsker D, Du-Thanh A, Terrail N, Dandurand M, Dereure O

Résumé

Lenalidomide (LND), a synthetic thalidomide analog mainly used in haematological malignancies has proved efficient and well-tolerated in small case series of refractory Cutaneous Lupus Erythematosus (CLE). A retrospective survey of CLE patients treated with low-dose LND in three institutional Departments of Dermatology was conducted to further assess the benefit/risk ratio of this molecule in this setting (Institutional Review Board for ethical issues of University Hospital of Montpellier 2018_IRB-MTP_11-01). Primary endpoints were best overall response (BOR) obtained with initial dosage or after dose adjustment and time to achieve BOR.

Mots clés

cutaneous lupus erythematosus, lenalidomide, neuropathy, refractory

Référence

J Eur Acad Dermatol Venereol. 2020 Jul 30;: